



1 October 2019

ASX Announcement / Media Release

Race appoints Dr Daniel Tillett Chief Scientific Officer

1 October 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC.

Dr Tillett recently anchored a share placement in RAC and was recently appointed as a Non-Executive Director of RAC. Because of his new executive responsibilities, Dr Tillett's Board role will change to Executive Director.

The CSO role at RAC was vacated by US-based Dr John Rothman during 2018. Dr Tillett will now fill that role and assume responsibility for RAC's overall R&D strategy, including manufacturing, and will assist the CEO in licensing discussions and with investor communications.

The CSO role is part-time, on average representing 40% of a full-time commitment by Dr Tillett. Dr Tillett has agreed to receive no cash compensation, but subject to shareholder approval, will receive 2.5 million options priced at \$0.19 each; the options expire three years from date of grant.

"Daniel is going to add huge value to Race over the next year, not only as an investor and director, but now also as Chief Scientific Officer," said Race CEO, Peter Molloy.

"I am very excited about taking a hands-on role with Race and helping get Bisantrene back into the clinic as quickly as possible. The more I have learned about Bisantrene the more potential I see it having in AML and other cancers. Teams as good as Race are rare in our industry and I couldn't turn down the opportunity to help." said Dr Daniel Tillett.

- ENDS -

About Dr Tillett

Dr Daniel Tillett is the founder and CEO of Nucleics (nucleics.com), a private Australian biotechnology company producing and selling world leading DNA sequencing software to the Genomics industry.

For personal use only

Nucleics SAAS (software as a service) tools are in use in more than 30 countries and over 250 companies and institutions. Dr Tillett has extensive commercial experience over the last 20 years in the biotech industry in project management, sales and marketing, IP management, fund raising and start-up investing. Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, microbiology, bioinformatics and cancer. Dr Tillett has a PhD from the University of New South Wales in Molecular Genetics and Biochemistry. He has more than 40 scientific publications and granted patents in molecular biology, microbiology, genetics and biochemistry.

About Race Oncology (RAC: ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned. Bisantrene has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US patents and a third allowed US patent. It has also been awarded US Orphan Drug designation and a 'Rare Paediatric Disease' (RPD) designation.

Media contact:

Heidi Cuthbert

+61 411 272 366

E: heidi.cuthbert@multiplier.com.au

For personal use only